OncoMed Halts Enrollment and Phase 1 Dosing Studies for Vantictumab and Fzd8-Fc

Treatment escalation plans can successfully be implemented into routine oncology practice, according to one study.

Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.

Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.